Acino’s business across the CIS region currently covers Ukraine, Russia, Kazakhstan, Belarus, Uzbekistan, Turkmenistan and Georgia, with a remarkable 25% sales growth for 2016 compared to 2015. Acino established its footprint in the region with the acquisition of Copharm in Russia in December 2014 and of Pharma Start in Ukraine in October 2015.
Acino Pharma Start develops, manufactures and commercializes a unique and patented portfolio of advanced generic drugs in the therapeutic areas of Cardiovascular, Central Nervous System (CNS), Women Health and Over-The-Counter products (OTC).
The site in Kiev is our regional headquarter and home to the commercial organization of Ukraine and the GMP-certified manufacturing plant.
Acino’s entity in Russia is a fast-growing pharmaceutical company with an exclusive portfolio of original products for diverse therapeutic areas focusing on female healthcare and cardiology. The business in Russia is managed via our regional office in Moscow.
Our commercial success in the region is built on a close and strong cooperation with key business partners, healthcare professionals and patients. We are committed to delivering health solutions to patients with high quality and maximum safety as well as educational activities for the healthcare community.